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The Nitric Oxide Donor DETA-NONOate
Decreases Matrix Metalloproteinase-9
Expression and Activity in Rat Aortic Smooth
Muscle and Abdominal Aortic Explants
Indranil Sinha, BA, Kevin K. Hannawa, BS, Gorav Ailawadi, MD, Derek T. Woodrum, MD,
John W. Ford, BA, Peter K. Henke, MD, James C. Stanley, MD, Matthew J. Eagleton, MD, and
Gilbert R. Upchurch, Jr., MD, Ann Arbor, Michigan
Our objective was to examine the role of an exogenous nitric oxide (NO) donor, DETA-NONOate
(DETA), on matrix metalloproteinase (MMP)-9, MMP-2, and tissue inhibitor of matrix metallo-
proteinases (TIMP)-1 expression and activity in interleukin (IL)-1b-induced rat aortic smooth
muscle cells (RA-SMCs) and rat aortic explants (RAEs). RA-SMCs were incubated with IL-1b
(2 ng/ml), an inflammatory cytokine known to induce MMP-9 expression, and increasing con-
centrations of DETA (0, 1.0, 10, 100 lM; n = 3/group) for 48 hr. RAEs were incubated with IL-1b
(2 ng/mL) and increasing concentrations of DETA (0, 5.0, 50, 100, and 500 lM; n = 3/group) for
48 hr. Media were collected and assayed for NOx by the Griess reaction and MMP-9 activity by
zymography. Messenger RNA (mRNA) was extracted from cells and analyzed for MMP-9, MMP-
2, and TIMP-1 expression levels by quantitative real-time reverse-transcriptase polymerase
chain reaction. All statistical analyses were performed by analysis of variance. In RA-SMCs and
RAEs, DETA administration resulted in a dose-dependent increase in media NOx concentration
(RA-SCM p < 0.01, RAE p < 0.01) and a concurrent decrease in both MMP-9 expression
(RASMC p = 0.01, RAE p = 0.01) and activity (RASMC p = 0.04, RAE p = 0.006). There were
no significant differences seen in MMP-2 and TIMP-1 expression or activity in response to DETA
exposure. DETA decreased IL-1b-induced MMP-9 expression and activity in both RA-SMCs and
RAEs in a dose-dependent fashion. In addition, DETA administration had no effect on MMP-2 or
TIMP-1 expression or activity in vitro. These data suggest that NO donors may be beneficial in
decreasing MMP-9 levels and might serve to inhibit MMP-9-dependent vessel wall remodeling
seen during abdominal aortic aneurysm formation.
INTRODUCTION
Nitric oxide (NO) is known to mediate many
physiological processes in vascular tissue. NO
inhibits vascular smooth muscle cell proliferation
and migration, neointima formation after vessel
injury, and extracellular matrix turnover.1-5 Col-
lectively, these events support the tenet that NO is
a major mediator of vessel wall remodeling.6
However, the interaction between NO and matrix
metalloproteinases (MMPs), a family of endopep-
tidases involved in the degradation of extracellular
matrix proteins, remains poorly understood. This
interaction may be important given observations
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suggesting the central importance of MMPs in the
development of abdominal aortic aneurysms
(AAAs).7-17 MMP-9, a 92 kDa gelatinase, has been
shown to be critical in the destructive process that
accompanies aneurysm development, as evidenced
by the inhibition of aneurysm formation following
elastase perfusion in mice with a targeted disrup-
tion of the MMP-9 gene.14,18 Levels of MMP-2 and
tissue inhibitor of metalloprotienases-1 (TIMP-1)
also may contribute to aneurysm pathogenesis. A
balance between MMPs and TIMP may in fact
control the pathological remodeling involved in
aneurysm formation.19
Previous studies have demonstrated that
increasing concentrations of the NO synthase
inhibitor NG-monomethyl-L-arginine (L-NMMA)
increases MMP-9 expression and activity in a dose-
dependent manner in rat aortic smooth muscle
cells (RA-SMCs) and rat aortic explants (RAEs).1,6
Furthermore, studies have shown that mice lacking
the inducible NO synthase (iNOS) gene appear to
develop experimental aortic aneurysms in an
accelerated fashion.20 Based on these data, we
hypothesized that increased NO levels would con-
versely serve to downregulate MMP-9. The objec-
tive of this study was to elucidate the ability of the
NO donor DETA-NONOate (DETA) to reduce
MMP-9 expression and activity in rat aortic tissue
and smooth muscle cells.
MATERIALS AND METHODS
Cell Culture
All experiments were performed with the approval
of the University of Michigan Committee on Labo-
ratory Animal Medicine. RA-SMCs were derived
from the abdominal aortas of young, male Sprague-
Dawley rats (Charles River Laboratories, Wilming-
ton, MA) by an explant method previously de-
scribed.1 Briefly, medial tissue was cut into 2 mm2
pieces and plated in tissue culture dishes. Culture
media included Dulbecco’s modified Eagle’s med-
ium (DMEM) containing 10% fetal bovine serum
(FBS) (HyClone Laboratories, Logan, UT), 100
units/mL penicillin, and 100 lg/mL streptomycin.
Media and antibiotics were from GIBCO (Rockville,
MD). Cultures were maintained at 37C in a
humidified, 5% CO2 atmosphere for 4-7 days. After
removing the explant, the remaining cells were
dispersed by treatment with Dispase (Collaborative
Research, Bedford, MA), centrifuged, and resus-
pended in complete medium, which was placed into
75 cm2 culture flasks. Reagents were obtained from
Sigma (St. Louis, MO) unless otherwise indicated.
Experimental conditions were carried out with
confluent RA-SMCs in serum-free medium sup-
plemented with antibiotics. Confluent monolayers
of RA-SMCs were costimulated in T-75 plates with
interleukin (IL)-1b, an inflammatory cytokine
known to induce MMP expression, at a physio-
logical concentration of 2 ng/mL and increasing
concentrations DETA (0, 1, 10, 100 lM; n = 3/
group). After 24 hr incubation, RA-SMCs were
lysed using TRIzol (Life Technologies, Rockville,
MD) and total cellular RNA was collected and
purified to messenger RNA (mRNA) to quantify
MMP-9, MMP-2, iNOS, and TIMP-1 expression.
After 48 hr incubation, RA-SMC conditioned
medium was collected for measurements of NOx,
MMP, and TIMP activity. The remaining RA-SMCs
were solubilized in 0.1% sodium dodecyl sulfate
(SDS), and total cellular protein was determined by
a bicinchoninic acid (BCA) protein assay (Pierce,
Rockford, IL).
Trypan blue dye exclusion assay was used to
measure cell viability. Confluent RA-SMCs were
removed from the culture flask by trypsinization
and centrifuged for 5 min at 1,100 rpm. The super-
natant was discarded and the pellet resuspended in
cold phosphate-buffered saline (PBS). Subse-
quently, 100 ll of suspension was transferred to a
1.5 mL Eppendorf tube, and 100 lL of 0.4% trypan
blue (Sigma) was added to the suspension. Next,
10 lL of this was transferred to each side of a
hemocytometer slide. Total numbers of cells and of
stained cells were determined. Viable cells were
noted as unstained cells.
Aortic Tissue Explants
Sprague-Dawley rats, weighing 300-350 g, were
anesthetized by inhalation of isoflurane (1-2%).
Through a midline abdominal incision, the infra-
renal aorta was exposed and the animals were
killed. Aortic tissue was excised, and explants were
supported by conventional means in tissue culture.
Each specimen was washed with PBS in a tissue
culture hood. Aortas were bisected longitudinally
to remove clotted blood from the lumen. Segments
were placed into separate wells of a 24-well tissue
culture plate. Aortic tissue was maintained in
DMEM with 100 units/mL penicillin and 100 lg/
mL streptomycin. All reagents were purchased
from Sigma, unless otherwise indicated. Tissue
culture media and antibiotics were obtained from
GIBCO. Tissues were incubated at 37C in humid-
ified, 5% CO2 atmosphere. After 24 hr, the tissue
was washed with PBS, and subsequently the
medium for the experimental condition was added.
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Experimental conditions were carried out in
serum-free media with 2 ng/mL IL-1b and
increasing concentrations of DETA (0, 5, 50, 100,
and 500 lm; n = 3/group). After 72 hr incubation,
aortas were lysed using TRIzol and total cellular
RNA was collected and purifed to mRNA to quan-
tify MMP, iNOS, and TIMP-1 expression (n = 3).
The experimental medium was collected for mea-
surements of NOx, MMP, and TIMP activity. For
aortas in which NOx content and MMP activity
assays were done, aortas were solubilized in 0.1%
SDS and total cellular protein was determined by
BCA protein assay.
Measurement of MMP and TIMP expression
mRNA was isolated by treatment of RA-SMCs and
RAEs with TRIzol reagent and reverse-transcribed by
incubating with oligo-(dT) primer (Invitrogen Life
Technologies, Grand Island, NY) and Moloney
murine leukemia virus reverse transcriptase (Invi-
trogen Life Technologies) at 94C for 3 min followed
by 40C for 70 min. The resultant complementary
DNA (cDNA) was amplified by Taq polymerase
(Promega, Madison, WI) in the SmartCycler quan-
titative polymerase chain reaction (PCR) system
(Cepheid, Sunnyvale, CA). SYBR Intercalating Dye
(Roche, Indianapolis, IN) was used to monitor levels
of cDNA amplification of each gene. SmartCycler
quantitation will be presented as cycle threshold
(Ct). MMP-2, MMP-9, TIMP-1, and b-actin primer
sequences were derived either from published liter-
ature sources or using Primer Premier Software
(Premier Biosoft International, Palo Alto, CA) based
on primary mRNA sequences from GenBank. The





3¢, MMP-2 sense 5¢-CATCGCTGCACCATCGCC-
CATCATC-3¢, MMP-2 antisense 5¢-CCCAGGGTC-
CACAGCTCATCATCATCA-3¢, TIMP-1 sense 5¢-
AATGCCACAGGTTTCCGGTTC-3¢, TIMP-1 anti-
sense 5¢-ACACCCCACAGCCAGCACTAT-3¢.
Results were normalized using the housekeeping
gene b-actin. For quantification of mRNA levels,
DCt values were calculated by the following for-
mula: DCt = Ct target gene ) Ct b-actin. Expression of
the target gene in ratio to b-actin expression was
calculated by the following formula: target gene/b-
actin = 2)(DCt). PCRs were repeated and analyzed in
triplicate for each of the experimental groups.
Substrate Gel Zymography and Reverse
Zymography
MMP distribution of treated RA-SMCs or treated
RAEs was determined by zymography using re-
agents from Novex (San Diego, CA) and the
experimental medium. Gelatin substrate zymo-
grams were prepared using precast 10% SDS-
polyacrylamide gels containing 1 mg/mL of gela-
tin. Experimental samples of equal volume were
diluted into 2 · Tris-glycine SDS sample buffer
and separated electrophoretically under nonre-
ducing conditions. Proteins were renatured in
2.7% Triton X-100 and the gels incubated for
varying time periods in order to best quantify the
desired MMP band at 37C in 50 mM Tris-HCl
containing 5 mM CaCl2 and 0.2% Brij 35. Fol-
lowing staining with Coomassie blue R-250 and
destaining with 10% acetic acid, gelatinase activ-
ity was evident as a clear band against a dark blue
background. RA-SMCs demonstrated pro-MMP-9
activity, whereas RAEs produced both pro-MMP-9
and active MMP-9.
Reverse zymography was performed to measure
TIMP-1 activity. Zymogram substrate was prepared
using 2 mg/mL porcine gelatin, 0.25 M Tris-HCl
(pH 8.8), 0.125% SDS, 0.5 lL/mL TEMED, 0.4 mg/
mL ammonium persulfate, 15% (w/v) acrylamide,
0.4% bisacrylamide, and 200 ng/mL of progela-
tinase A (Oncogene, Boston, MA). A standard 4%
polyacrylamide stacking gel was used. Experimen-
tal samples of equal volumes were diluted into 2 ·
Tris-glycine SDS sample buffer and separated elec-
trophoretically under nonreducing conditions.
Proteins were renatured in three changes of 2.7%
Triton X-100 for 60 min each. Gels were incubated
for 17 hr at 37C in 50 mM Tris-HCl, 5 mM CaCl2,
and 0.2% Brij 35. Gelatinase inhibitory activity was
noted as a blue band on a clear background fol-
lowing staining with Coomassie blue R-250 and
destaining with 10% acetic acid.
The relative molecular weight of each band was
determined by comparison of the bands against
MMP-2 (72 kDa), MMP-9 (92 kDa), and TIMP-1
(29 kDa) standards (Oncogene). Semiquantitative
measurements of MMP activity were performed by
densitometry and normalized to total cellular pro-
tein. MMP activity was quantified by densitometry.
All gel images were acquired using a FOTO/Analyst
charge-coupled device camera (Fotodyne, Hart-
land, WI). Band strength was quantified using
GEL-Pro Analyzer software, version 3.1 (Media
Cybernetics, Silver Spring, MD).
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RESULTS
DETA Administration Increases NO Levels
and Decreases MMP-9 Expression and
Activity in RA-SMCs
DETA caused an increase in NOx levels of 72% in
the 100 lM DETA group compared to IL-1b alone
(p < 0.01, figure not shown). DETA alone without
costimulation with IL-1b caused no change in
MMP-2, MMP-9, or TIMP-1 expression and activ-
ity. Conversely, cell cultures costimulated with IL-
1b and increasing concentrations of DETA dem-
onstrated a decrease in MMP expression of 49% in
the 100 lM DETA-treated group in comparison to
IL-1b alone (p = 0.01, Fig. 1a). There was a con-
current 58% decrease in pro-MMP-9 activity in the
100 lM DETA group in comparison to IL-1b alone
as measured by gel substrate zymography
(p = 0.04, Fig. 1b). There were no significant dif-
ferences in either MMP-2 or TIMP-1 expression or
activity (data not shown). No statistically signifi-
cant differences in cell viability were noted among
any of the treatment groups.
DETA Administration Increases NO and
Decreases MMP-9 Expression and Activity in
RAEs
NOx levels increased in a dose-dependent manner
in relation to DETA exposure. In RAEs treated with
500 lM DETA, the NOx concentration increased
502% compared to IL-1b alone (p < 0.01, figure not
shown). MMP-9 expression demonstrated a dose-
dependent decrease (p = 0.01, Fig. 2a), with the
100 lM and 500 lM DETA-treated groups experi-
encing 70% and 78% decreases, respectively.
Similarly, there was a significant decrease in
total pro-MMP-9 activity in both the 100 lM and
500 lM DETA-treated groups (69% and 72%,
respectively, compared to the control group). Pro-
MMP-9 activity decreased in a dose-dependent
relationship to exogenous NO administration
(p = 0.006, Fig. 2b). Active-MMP-9 also decreased
in response to DETA exposure (p = 0.015, Fig. 2c),
with no active MMP-9 being detectable in the
500 lM DETA-treated group. There was no signif-
icant difference in either MMP-2 or TIMP-1





























































response to increasing doses of
DETA (*p = 0.01). b In RA-
SMCs, pro-MMP-9 activity, as
measured by zymography,
decreases with increasing
doses of DETA (*p = 0.04).
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DISCUSSION
This study demonstrates that exposure to exoge-
nous NO, using the NO donor DETA, decreases
both MMP-9 expression and activity in a dose-
dependent manner in both RA-SMCs and RAEs.
Importantly, expression and activity for MMP-2
and TIMP-1 did not change in response to
increasing DETA exposure. These data suggest that
MMP-9 in RA-SMCs and RAEs is selectively
inhibited by increased local bioavailable NO in the



















































































Fig. 2. a In RAEs, MMP-9/b-
actin mRNA expression by
real-time PCR demonstrated a
significant dose-dependent
decrease in expression in
response to increasing doses
of DETA (*p = 0.01). b In
RAEs, pro-MMP-9 activity, as
measured by zymography,
decreases in a dose-dependent
manner with increasing doses
of DETA (*p = 0.006). c In
RAEs, cleaved or active MMP-
9 activity, as measured by
zymography, decreases with
increasing doses of DETA.
Cleaved MMP-9 is not
detectable in the 500 lM-
treated group (*p = 0.015).
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AAAs are characterized by structural alterations
of the aortic wall resulting, in part, from the deg-
radation of collagen and elastin.18 An inflammatory
infiltrate and overexpression of MMPs are impor-
tant factors involved in the pathological vascular
remodeling accompanying AAA develop-
ment.6,16,18 MMP-9 has been shown to be especially
critical in this process.16,17 Previous in vitro studies
have suggested that NO, a ubiquitous free radical,
modulates MMP-9 expression and its corresponding
physiological effects. In this study, addition of
100 lM and 500 lM DETA resulted in supraphysi-
ological NO levels of twofold and sixfold, respec-
tively, in comparison to IL-1b alone. It has also been
shown that endothelial NOS gene transfer into RA-
SMCs inhibits both MMP-2 and MMP-9 activity and
limits SMC migration.22 Knipp et al.23 demon-
strated that selective iNOS inhibition in
IL-1b-induced rat SMCs decreases MMP-9 expres-
sion through a nuclear factor jB (NF-jB)-depen-
dent mechanism.
Studies in human tissue further support an
associative role for NO in the formation of AAAs.
Paik and Tilson24 were the first to suggest a role for
NO in AAAs. Knipp and colleagues25 demonstrated
that patients with AAAs, compared to well-mat-
ched patients with peripheral vascular occlusive
disease and normal controls, sustain decreased
endothelium- and non-endothelium-dependent
relaxation in areas remote from the AAA (i.e.,
brachial artery). This occurred paradoxically in the
setting of increased circulating levels of NO. Troxler
and others26 documented increased circulating
levels of nitrotyrosine in patients undergoing AAA
repair. Importantly, following AAA repair, circu-
lating nitrotyrosine returned to control levels,
suggesting that the aneurysm served as the source
of increased NO. Finally, data from other vascular
beds (e.g., cerebral) have also verified altered NOS
in association with an increased risk of human
aneurysms.27,28
Attempting to sort out the exact role of NO using
experimental aneurysm models has been both
confusing and problematic. A study using DNA
array technology in the elastase- perfused rodent
aortic aneurysm model clearly documented a role
for iNOS by demonstrating that this gene was up-
regulated compared to controls 52- and 5.2-fold on
postoperative days 2 and 7, respectively.29 Lee and
others20 extended this observation by documenting
accelerated aneurysm formation in iNOS)/) mice
but only in females. In contrast, other in vivo
studies in the rodent elastase model using both
nonselective30 and selective31 iNOS inhibitors
demonstrated that iNOS inhibition limits aortic
expansion. This decrease in AAA size occurred in
the setting of documented increases in arterial
blood pressure (i.e., decreases in NO concentra-
tions).
While the present in vitro and ex vivo results are
the first to document that increased NO decreases
MMP-9 expression and activity, the exact relation-
ship between NO and MMP-9 remains complicated.
More experiments are needed to determine the exact
mechanism(s) responsible for the paradoxical effects
of NO on MMP-9. Earlier experiments from our
laboratory suggest a role for NF-jB and activator
protein-1.23 Another study demonstrated that NO
may inhibit MMP-9 expression and activity via
inhibition of the extracellular signal-regulated ki-
nase (ERK) pathway in RA-SMCs.32 However, fur-
ther studies are necessary to fully elucidate the
interaction between NO and MMP-9. For example, it
will be important to confirm if NO acts directly on
MMP-9 or if it works through the increased gener-
ation of reactive oxygen species, such as peroxyni-
trite. Finally, delivery of NO to in vivo tissue is very
problematic for a number of reasons, including NO’s
extremely short half-life. Attempts (data not shown)
were made to translate the current in vitro and ex
vivo findings using NO donors to the rodent aortic
elastase perfusion model. Unfortunately, despite
using multiple dosing schedules, multiple concen-
trations of the drug, and various delivery methods
(intra-arterial and intraperitoneal), we were unable
to reliably inhibit AAA formation in the rodent
aneurysm model. Given these difficulties in limiting
aneurysmal growth in a rodent model, it is uncertain
whether NO and MMP have a clinically significant
interaction in human AAA development. Despite
our inability to document an in vivo effect on AAA
formation in the rodent, understanding the inter-
actions between complex enzymes such as the
MMPs and NO synthases involved in AAA pathology
may help to promote pharmacological treatments for
limiting AAA growth.
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